WallStreetZenWallStreetZen

NASDAQ: REVB
Revelation Biosciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their REVB stock forecasts and price targets.

Forecast return on equity

Is REVB forecast to generate an efficient return?
Company
-54.47%
Industry
75.88%
Market
80.85%
REVB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is REVB forecast to generate an efficient return on assets?
Company
-35.1%
Industry
31.13%
REVB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

REVB earnings per share forecast

What is REVB's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$7.54
Avg 2 year Forecast
-$5.24
Avg 3 year Forecast
-$3.58

REVB revenue forecast

What is REVB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$34.7M
Avg 2 year Forecast
$34.7M
Avg 3 year Forecast
$73.2M

REVB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REVB$2.40N/AN/A
AZTR$0.14N/AN/A
TCBP$0.80N/AN/A
ENSC$0.53N/AN/A
NEXI$2.80N/AN/A

Revelation Biosciences Stock Forecast FAQ

What is REVB's earnings growth forecast for 2024-2026?

(NASDAQ: REVB) Revelation Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19%.

Revelation Biosciences's earnings in 2024 is -$8,960,882.On average, 2 Wall Street analysts forecast REVB's earnings for 2024 to be -$12,304,165, with the lowest REVB earnings forecast at -$15,725,164, and the highest REVB earnings forecast at -$8,883,166. On average, 2 Wall Street analysts forecast REVB's earnings for 2025 to be -$8,548,415, with the lowest REVB earnings forecast at -$11,430,545, and the highest REVB earnings forecast at -$5,666,284.

In 2026, REVB is forecast to generate -$5,845,907 in earnings, with the lowest earnings forecast at -$5,845,907 and the highest earnings forecast at -$5,845,907.

If you're new to stock investing, here's how to buy Revelation Biosciences stock.

What is REVB's revenue growth forecast for 2027-2029?

(NASDAQ: REVB) Revelation Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.87%.

Revelation Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast REVB's revenue for 2027 to be $56,648,148, with the lowest REVB revenue forecast at $56,648,148, and the highest REVB revenue forecast at $56,648,148. On average, 1 Wall Street analysts forecast REVB's revenue for 2028 to be $56,646,515, with the lowest REVB revenue forecast at $56,646,515, and the highest REVB revenue forecast at $56,646,515.

In 2029, REVB is forecast to generate $119,547,171 in revenue, with the lowest revenue forecast at $119,547,171 and the highest revenue forecast at $119,547,171.

What is REVB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: REVB) forecast ROA is -35.1%, which is lower than the forecast US Biotechnology industry average of 31.13%.

What is REVB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: REVB) Revelation Biosciences's current Earnings Per Share (EPS) is -$35.99. On average, analysts forecast that REVB's EPS will be -$7.54 for 2024, with the lowest EPS forecast at -$9.63, and the highest EPS forecast at -$5.44. On average, analysts forecast that REVB's EPS will be -$5.24 for 2025, with the lowest EPS forecast at -$7.00, and the highest EPS forecast at -$3.47. In 2026, REVB's EPS is forecast to hit -$3.58 (min: -$3.58, max: -$3.58).

What is REVB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: REVB) forecast ROE is -54.47%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.